Tricyclic benzazepine vasopressin antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

544344, 544346, A61K 31495, A61K 3150, C07D24136, C07D47100

Patent

active

057804710

ABSTRACT:
Tricyclic diazepines of the Formula I: ##STR1## wherein A, B, D, E, F, Y, and Z are defined in the specification which compounds have vasopressin and oxytocin antagonist activity.

REFERENCES:
patent: 3763183 (1973-10-01), Carabateas
patent: 4766108 (1988-08-01), Ali
patent: 5055448 (1991-10-01), Manning et al.
patent: 5070187 (1991-12-01), Gavras et al.
patent: 5258510 (1993-11-01), Ogawa et al.
patent: 5516774 (1996-05-01), Albright et al.
J. Med. Chem., 1992,35, 3905-3918, Williams et al.
J. Med. Chem., 1992, 35, 3895-3904-Manning et al.
J. Med. Chem., 1992, 35, 382-388, Manning et al.
From Vasopressin Antagonist to Agonist, DN + P 4(4), May 1991, Ruffolo et al.
Br. J. Pharmacol. (1992), 105, 787-791, Yamamura et al.
Science, vol. 252, pp. 572-574, Yamamura et al.
J. Med. Chem., 1992, 35, 3919-3927, Evans et al.
J. Med. Chem., 1993, 36, 3993-4005, Evans et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Tricyclic benzazepine vasopressin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic benzazepine vasopressin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic benzazepine vasopressin antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1881998

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.